Work

A novel synthetic derivative of biaryl guanidine as a potential BACE1 inhibitor, to treat Alzheimer’s disease: In-silico, in-vitro and in-vivo evaluation

Year: 2022

Type: article

Abstract: 6±0.56 µM) and active to arrest (99 %) β-secretase enzyme (FRET assay). Furthermore, it was found to improve novel object recognition test (RTI =56.55%) and Morris water maze test (32.26±3.45s) significantly (p<0.05). Enhanced pharmacokinetics and related properties (high iLOGP and Log S =-3.98) along with improved permeation to the blood brain barrier (BBB) (zero Lipinski violation) made it feasible to inhibit BACE1 as a novel therapeutic source to treat AD in future.

Source: Pakistan Journal of Pharmaceutical Sciences

DOI: 10.36721/pjps.2022.35.5.reg.1339-1345.1

Authors: Sayyad Ali, Muhammad Hassham Hassan Bin Asad, Muhammad Arslan Javed, Tariq Javed, Yasser Msa Al-Kharaman, Muhammad Latif, Sabeeh Mohsin, Taufiq Nawaz, Syed Muhammad Farid Hasan, Jamshed Iqbal, Borhan Babak, Izhar Hussain

Institutions: COMSATS University Islamabad, Michigan State University, Services Institute of Medical Sciences, Services Hospital, University of Health Sciences Lahore, University of Okara, University of Education, The University of Agriculture, Peshawar, University of Karachi

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4310595209

FWCI: 0.453

Cites:

Cited by: 3

Related to: 10